Nanomaterials in Theranostics: Global Markets

Nanomaterials in Theranostics: Global Markets

BCC, Date of Publication: Jul 25, 2013, 170 Pages
US$6,650.00
GB-HLC144A

This study provides a comprehensive analysis of the nanomaterial market for use in theranostics and personalized medicine. Theranostics is the fusion of therapy and diagnosis; it is the foundation of personalized medicine, which is a newly proposed model of highly customized healthcare. This study describes this model in detail and analyzes a large selection of nanomaterials that play various roles in the market, including proteins, monoclonal antibodies, nanoparticles, nanocrystals, liposomes and quantum dots.

This market is increasing exponentially in size and revenues, and it is changing the standards of the healthcare model, thus imposing new marketing tactics, strategic alliances, innovative business models and research and development (R&D) outsourcing paradigms.

This report addresses the drivers and limiters of this new model and offers an exhaustive analysis of the nanomaterials used in theranostics.

REASON FOR DOING THE STUDY

Theranostic and personalized medicine will be the ultimate transformation of modern healthcare to diagnose and treat diseases. Nanotechnology will be the toolbox used to execute this new approach to medicine. The report analyzes the market and includes historical sales of all the nanomaterials used in theranostics in 2011 and 2012. Sales are forecast through 2017.

This study in an invaluable instrument for understanding the ways in which the pharmaceutical and medical device markets are rapidly changing by forming new paradigms and marketing strategies. The market is characterized by the creation of partnerships, collaborations and mergers and acquisitions (M&A) between pharmaceutical companies, the medical device industries, academics and small startups. Seventeen new emerging geographic markets, including Russia, India, China, Turkey, South Africa and Thailand, are also discussed.

SCOPE OF THE REPORT

Blockbuster and one–size-fits-all drugs are slowly exiting the market to make room for the era of personalized medicine. Theranostics, which is the fusion of therapeutics and diagnostics, is the foundation of personalized medicine in which specific therapies are tailored to patients to treat diseases based on their genetic makeups and/or to determine which therapies will have the fewest side effects. Nanotechnology will play a pivotal role in this revolution, and the global market for nanomaterials used in theranostics will be more than $187 billion in 2017, increasing at a compound annual growth rate (CAGR) of 10.8%

Monoclonal antibodies will comprise the largest segment for the biologic nanomaterials, and liposome will be the largest segment for non-biologic nanomaterials. Other nanomaterials discussed in this report include fullerene C60, carbon nanotubes, quantum dots, gold nanoparticles and proteins.

Profiles of key market players and small startups are also included. Major products that generate the largest revenues, as well as the most-valuable R&D products that will come on the market up to 2017 are provided.

In-depth competitive market analysis is discussed, with examples of how new products will enter the market or how existing products will survive or perish. The report also includes a very detailed description of current and future technologies for the preparation of nanomaterials in theranostics.

INTENDED AUDIENCE

The report is intended for professionals in the medical, medical devices, pharmaceutical, nanotechnology, materials, chemical, biological, biotechnological and diagnostics fields. It allows readers to understand the paradigms of personalized medicine’s new business model. A discussion of the debate between the marketing of a drug with or without its companion diagnostic kit is included. Therefore, this report is valuable for both the pharmaceutical and the medical devices industries.

Additional professionals who may benefit from reading this report include analysts, sales and marketing representatives, R&D personnel, business development personnel and corporate strategy developers. Investment firms will gain invaluable information concerning risks and opportunities encountered in the field.

The report provides valuable insights and guidance for strategic marketing planning, driver and limiter understanding, and sales growth opportunities.

METHODOLOGY AND INFORMATION SOURCE

A bottom-up approached was used to calculate the global market size of nanomaterials for use in theranostics.

Primary and secondary research was conducted using patent literature, paid and open-access academic literature, books, press (e.g., New York Times, Wall Street Journal) SEC filings, companies’ annual reports and press releases.

Interviews with experts in the field were conducted, including analysts, heads of investor relations and professors.

Additional statistical data and general information were obtained from the National Science Foundation, the National Institutes of Health (NIH), the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), IMS Health and the Congressional Budget Office.


TABLE OF CONTENTS

Chapter 1: INTRODUCTION

    STUDY GOALS AND OBJECTIVE
    REASON FOR DOING THE STUDY
    SCOPE OF THE REPORT
    INTENDED AUDIENCE
    METHODOLOGY AND INFORMATION SOURCE
    ANALYST CREDENTIALS
    RELATED REPORTS
    DISCLAIMER

Chapter 2: SUMMARY     

        Table Summary : GLOBAL THERANOSTIC NANOMATERIAL MARKET, THROUGH 2017
        Figure Summary : GLOBAL THERANOSTIC NANOMATERIAL MARKET, 2011-2017

Chapter 3: OVERVIEW

    THERANOSTICS AND PERSONALIZED MEDICINE OVERVIEW
            Table 1 : THERAPIES WITH DIAGNOSTIC COMPANION KITS
            Figure 1 : RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED
    NANOPARTICLES
        PASSIVE TARGETING
        ACTIVE TARGETING
    NANOTECHNOLOGY OVERVIEW
        NANOTECHNOLOGY PRODUCTS ON THE MARKET
        SIZE DEFINITION
        SHAPE
        SURFACE AREA
        QUANTUM DOTS
        CARBON NANOTUBES
        MULTIFUNCTIONAL NANOMATERIALS
    NANOTHERANOSTICS OVERVIEW
        GOLD-BASED NANOMATERIALS
        MAGNETIC NANOMATERIALS
        POLYMERIC NANOMATERIALS
        SILICA-BASED NANOMATERIALS
        CARBON NANOMATERIALS
        COMPOSITE NANOMATERIALS
        BIOLOGIC NANOMATERIALS: ANTIBODY, PROTEINS AND DNA
        OTHER NANOMATERIALS
            Table 3 : MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD
            Table 4 : NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017
    DRUG DELIVERY
            Table 5 : MAJOR NANOMATERIAL APPLICATIONS IN THERANOSTICS

Chapter 4: GLOBAL NANOMATERIAL THERANOSTICS MARKET

    GLOBAL MONOCLONAL ANTIBODIES IN THERANOSTICS MARKET
    GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTICS IMAGING SYSTEMS
    GLOBAL REVENUES FOR DRUG DEVELOPMENT AND FORMULATION
    GLOBAL MAGNETIC RESONANCE IMAGING REAGENT MARKET
    GLOBAL IN VITRO OPTICAL IMAGING REAGENT MARKET
    GLOBAL GOLD-BASED MATERIALS USED AS NANOCARRIERS MARKET
    GLOBAL LIPOSOMAL-BASED MATERIALS USED AS NANOCARRIERS MARKET
    GLOBAL NANOCRYSTAL DRUG MARKET
    GLOBAL BLOCKBUSTER ANTIBODY DRUG MARKET
        Table 6 : GLOBAL NANOMATERIAL THERANOSTIC MARKET, THROUGH 2017
        Figure 2 : TITLE GLOBAL NANOMATERIAL THERANOSTIC MARKET, 2011-2017

Chapter 5: NANOTHERANOSTIC DRUG DELIVERY         

    INTRODUCTION
    IN VIVO DRUG RELEASE STUDIES
    DRUG EFFICACY
    FUTURE DIRECTIONS

Chapter 6: NANOMATERIAL STRUCTURES, CHARACTERISTICS AND METHODS OF PREPARATION

    CARBON NANOTUBES
        CARBON NANOTUBES AS CARRIERS OF IMMUNOACTIVE COMPOUNDS, PROTEINS AND GENETIC MATERIALS
        CANCER PHOTOTHERMAL THERAPY
        CARBON NANOTUBES FOR OTHER THERAPEUTIC APPLICATIONS
    FULLERENE C60
        C60 TOXICITY
        UPTAKE AND BIODISTRIBUTION
        ANTIOXIDANT PROPERTIES
        ENDOHEDRALS
        MAGNETIC RESONANCE IMAGING
        RADIONUCLIDES
        PHOTODYANIMC THERAPY
        DNA PHOTOCLEAVAGE
        CANCER
        INHIBITION OF ENZYMES, VIRUSES AND BACTERIA
        DRUG AND GENE DELIVERY
    PROTEINS
        ENZYMES
    MONOCLONAL ANTIBODIES
        MONOCLONAL ANTIBODY THERAPY
            Table 20 : MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET
    NANOMATERIALS IN THERANOSTICS
            Table 22 : MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT
            Table 23 : NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017
    GOLD NANOPARTICLES
        GOLD NANOCARRIERS
        HYPERTHERMIA
        CONTRAST ENHANCERS
        RADIOTHERAPY
    MAGNETIC NANOPARTICLES
        HYPERTHERMIA
        MAGNETIC SEPARATION
        IMAGING AND DELIVERY
        BRAIN TUMOR DELIVERY
        PROSTATE CANCER
        BLADDER TUMOR
    LIPOSOMES
        LIPOSOME CLASSIFICATION AND PREPARATION
        STEALTH LIPOSOME
        ANTIBODY-LIPOSOME CONJUGATE
            Table 25 : LIPOSOME ADVANTAGES
    NANOCRYSTALS
        NANOCRYSTALS FABRICATION
            Table 28 : NANOCRYSTAL PROPERTIES
            Table 29 : NANOCRYSTAL DRUG FEATURES
    QUANTUM DOTS
        QUANTUM DOTS NANOCARRIER
        PHOTOPHYSICAL PROPERTIES: DRUG-DELIVERY AND DRUG-RELEASE SENSING
    MULTIFUNCTIONAL NANOPARTICLES
        POLYMERIC NANOPARTICLES IN CANCER THERAPY
    QUANTUM DOTS IN CANCER IMAGING AND THERAPY
        QUANTUM DOTS IN PHOTODYNAMIC THERAPY AND IMAGING
    MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR CANCER IMAGING AND THERAPY
    MAGNETIC NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING AND GENE DELIVERY
    MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOHYBRIDS FOR CANCER IMAGING AND THERAPY
    GOLD NANOMATERIALS FOR PHOTOTHERMAL THERAPY
    GOLD NANOSHELLS
    GOLD NANORODS
    MAGNETIC GOLD NANOSHELLS FOR PHOTOTHERMAL THERAPY AND IMAGING

Chapter 7: NANODEVICES AND NANOMATERIALS FOR DIAGNOSTICS

    OVERVIEW
        MOLECULAR RECOGNITION IN DIAGNOSIS
        NANOPATTERNED DEVICES
        PARTICLES
    DIAGNOSTIC AND MEDICAL DEVICE INDUSTRY
    CONCLUSIONS AND FUTURE TRENDS

Chapter 8: NANOMATERIAL-BASED TREATMENTS FOR INFECTIONS ASSOCIATED WITH MEDICAL DEVICES

    INFECTIONS ASSOCIATED WITH MEDICAL DEVICES AND THEIR TREATMENTS
        CATHETER-ASSOCIATED INFECTIONS
        SOFT-TISSUE-IMPLANT-ASSOCIATED INFECTIONS
        BIOFILM FORMATION
        COMMON METHODS FOR PREVENTING AND TREATING MEDICAL DEVICE-ASSOCIATED INFECTIONS
        NANOMATERIALS IN MEDICAL APPLICATIONS
        CYTOTOXICITY CONSIDERATION

Chapter 9: THERANOSTIC REGULATORY FRAMEWORKS

    OVERVIEW
        NANOPRODUCT PHYSICOCHEMICAL PROPERTY DIFFERENCES COMPARED TO THEIR LARGER COUNTERPARTS
        REGULATORY ISSUES IN NANOTECHNOLOGY

Chapter 10: COMPETITIVE ANALYSIS

    INTRODUCTION
    CONTRACT MANUFACTURING ORGANIZATIONS
    INFORMATION TECHNOLOGY
    ONCOLOGY
        BIOSIMILARS VERSUS GENERICS
        ANTIRHEUMATICS MARKET
        EMERGING MARKETS
            Table 34 : GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017
            Table 35 : BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION

Chapter 11: COMPANY PIPELINES

        Table 39 : PROTEIN DRUGS
        Table 40 : NANOPARTICLES DRUGS

Chapter 12: THERAPY AND DIAGNOSTICS COMPANION KITS   


Chapter 13: PATENT STATUS     

        Table 41 : PATENTS BY TECHNOLOGY, 2001-2012
        Table 42 : QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY
        Table 43 : GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY

Chapter 14: DRIVERS AND LIMITERS

    DRIVERS
    LIMITERS

Chapter 15: COMPANY PROFILES

    AFFYMETRIX
    A.P. PHARMA INC.
    ABRAXIS BIOSCIENCES INC.
    ACUSPHERE INC.
    ACCUTHERANOSTICS
    ADVANCED PROTEOME THERAPEUTICS INC.
    ADVANCED RESEARCH TECHNOLOGIES INC.
    AFFIBODY AB
    AGENIX LTD.
    ALNYLAM PHARMACEUTICALS INC.
    ALSERES PHARMACEUTICALS INC.
    AMAG PHARMACEUTICALS INC.
    AMBRY GENETICS
    APHIOS CORPORATION
    ALACRIS THERANOSTICS GMBH
    ALZA CORP.
    ARROWHEAD RESEARCH CORPORATION
    ASKLEPIOS BIOPHARMACEUTICAL INC.
    ASTELLA PAHRMA INC.
    ASTRAZENECA PHARMACEUTICALS PLC
    ATREUS PHARMACEUTICALS CORPORATION
    AXXAM SPA
    BAYER HEALTHCARE AG
    BECKMAN COULTER
    BIOMERIEUX
    BIONKIT LTD.
    BBI INTERNATIONAL
    BIND BIOSCIENCES INC.
    BIOPAL
    CERULEAN PHARMA INC.
    CYTIMMUNE
    DEBIOTECH, S.A.
    ELAN PHARMACEUTICALS INC.
    EISAI
    EPIGENOMICS AG
    FLAMEL TECHNOLOGIES INC.
    FUJIFILM KYOWA KIRIN CO LTD.
    GENOMIC HEALTH
    GILEAD
    GE GLOBAL RESEARCH
    GSK SMITHKLINE
    INGEN BIOSCIENCES
    INNOVA BIOSCIENCES
    INSIGHT GENOMICS
    IPSEN
    IZON
    JANSSEN BIOTECH INC.
    JOHNSON & JOHNSON
    LAB 21
    LIQUIDIA TECHNOLOGIES INC.
    MAGFORCE NANOTECHNOLOGIES AG
    MERCK
    MONOGRAM BIOSCIENCES
    NANOCS
    NANOCARRIER CO. LTD.
    NANOCOMPOSIX
    NANOPARTZ INC.
    NANOPROBES INC.
    NANOSPHERE INC.
    NANOSIGHT LTD.
    NANOTHERAPEUTICS
    NEKTAR
    NOVARTIS INTERNATIONAL AG
    OCEAN NANOTECH
    PACIFIC BIOMARKERS
    PARTICLE SCIENCES
    PFIZER
    PHARNEXT
    SANOFI
    SELECTA BIOSCIENCE
    SOLUBEST
    SURMODICS INC.
    SKYEPHARMA PLC
    STARPHARMA HOLDINGS LTD.
    T2 BIOSTEMS INC.
    TALON THERAPEUTICS INC.
    TAKEDA
    THERANOSTIC HEALTH
    THERANOSTICS LAB LTD.

 
List of Tables

    Summary Table : GLOBAL THERANOSTIC NANOMATERIAL MARKET, THROUGH 2017
    Table 1 : THERAPIES WITH DIAGNOSTIC COMPANION KITS
    Table 2 : NANOMATERIAL TYPES
    Table 3 : MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD
    Table 4 : NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017
    Table 5 : MAJOR NANOMATERIAL APPLICATIONS IN THERANOSTICS
    Table 6 : GLOBAL NANOMATERIAL THERANOSTIC MARKET, THROUGH 2017
    Table 7 : GLOBAL MONOCLONAL ANTIBODY MARKET, THROUGH 2017
    Table 8 : GLOBAL PROTEIN MARKET, THROUGH 2017
    Table 9 : GLOBAL DIAGNOSTIC IMAGING AND TESTING NANOPARTICLE MARKET, THROUGH 2017
    Table 10 : GLOBAL DRUG-DEVELOPMENT AND FORMULATION NANOPARTICLE MARKET, THROUGH 2017
    Table 11 : GLOBAL IRON-OXIDE NANOPARTICLES USED AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS MARKET, THROUGH 2017
    Table 12 : GLOBAL NANOMATERIALS USED AS IN VITRO OPTICAL IMAGING REAGENTS MARKET, THROUGH 2017
    Table 13 : GLOBAL GOLD-BASED NANOMATERIALS USED AS CARRIERS MARKET, THROUGH 2017
    Table 14 : GLOBAL LIPOSOME-BASED MATERIALS USED AS DRUG CARRIERS MARKET, THROUGH 2017
    Table 15 : GLOBAL NANOCRYSTAL DRUG MARKET, THROUGH 2017
    Table 16 : GLOBAL MONOCLONAL ANTIBODY BLOCKBUSTER DRUG MARKET, THROUGH 2017
    Table 17 : EXAMPLES OF NANOMATERIALS USED IN THERANOSTICS
    Table 18 : IMAGING MODALITIES USED IN THERANOSTIC NANODEVICES
    Table 19 : NON-MONOCLONAL ANTIBODY PROTEINS
    Table 20 : MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET
    Table 21 : GLOBAL MONOCLONAL ANTIBODY MARKET
    Table 22 : MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT
    Table 23 : NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017
    Table 24 : U.S. FOOD AND DRUG ADMINISTRATION-APPROVED NANOPARTICLE DRUG-DELIVERY SYSTEMS
    Table 25 : LIPOSOME ADVANTAGES
    Table 26 : LIPOSOME-BASED DRUGS
    Table 27 : MAJOR PLAYERS IN THE LIPOSOME MARKET
    Table 28 : NANOCRYSTAL PROPERTIES
    Table 29 : NANOCRYSTAL DRUG FEATURES
    Table 30 : NANOCRYSTAL MANUFACTURING TECHNOLOGIES
    Table 31 : NANOCRYSTAL DRUGS CURRENTLY ON THE MARKET
    Table 32 : KEY PLAYERS IN THE IN VITRO DIAGNOSTIC MARKET
    Table 33 : KEY PLAYERS IN THE DIAGNOSTIC IMAGING MARKET
    Table 34 : GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017
    Table 35 : BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION
    Table 36 : BLOCKBUSTER MONOCLONAL ANTIBODIES FOR THE ANTIRHEUMATIC MARKET, THROUGH 2017
    Table 37 : KEY PLAYERS IN THE GENERIC MARKET
    Table 38 : COMPANY EVENTS IMPACTING THE THERANOSTIC MARKET
    Table 39 : PROTEIN DRUGS
    Table 40 : NANOPARTICLES DRUGS
    Table 41 : PATENTS BY TECHNOLOGY, 2001-2012
    Table 42 : QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY
    Table 43 : GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY
    Table 44 : THERANOSTIC MARKET DRIVERS
    Table 45 : THERANOSTIC MARKET LIMITERS

List of Figures

    Summary Figure : GLOBAL THERANOSTIC NANOMATERIAL MARKET, 2011-2017
    Figure 1 : RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED
    Figure 2 : TITLE GLOBAL NANOMATERIAL THERANOSTIC MARKET, 2011-2017

 

Date of Publication:
Jul 25, 2013
File Format:
PDF via E-mail
Number of Pages:
170 Pages
Type the characters you see in the picture above.